Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus Screening Targets for Almirall

NEW YORK (GenomeWeb News) – BioFocus will use its screening technologies and compound collections to find new hit compounds against key targets of interest for Barcelona, Spain-based pharmaceutical firm Almirall under a new agreement announced today.

Almirall said that BioFocus will help it find new hit compounds against key targets as possible treatments for respiratory and inflammatory conditions.

BioFocus has three research centers in the UK, Switzerland, and the Netherlands.
The Spanish drug developer focuses its efforts on asthma, COPD, gastrointestinal disorders, psoriasis, and other dermatological conditions.

Financial terms of the agreement were not released.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.